Updates
** Shares of vaccine makers rise after FDA leaders' comments on new guidelines for approval of COVID boosters
** Shares of Moderna MRNA.O up 8.5% at $28.62, Pfizer PFE.N up 2.2% at $23.50 and Novavax NVAX.O up 1.5% at $7.86
** U.S. FDA plans to mandate new placebo-controlled clinical trials for approval of annual COVID boosters for Americans under 65 in good health
** For adults over the age of 65 years, data, FDA can approve based on data from tests that measure immune response in patients
** "In the big picture this actually eases some investor concern for 2025 guidance to some extent," Jefferies analyst Michael Yee says
** FDA advisers also scheduled to discuss on Thursday whether to recommend COVID-19 vaccines for 2025-26 for targeting the LP.8.1 subvariant
** LP.8.1 strain is spreading faster than other variants, becoming dominant in different parts of the world, including the U.S. and Europe
** Including session's moves, MRNA down 31.6%, PFE down 11.5% and NVAX down 2.9% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.